z-logo
Premium
Functional outcomes after robot‐assisted pyeloplasty for ureteropelvic junction obstruction: A bi‐centre experience
Author(s) -
Popelin MarieBérénice,
Pinar Ugo,
Benamran Daniel,
Ingels Alexandre,
Parra Jérome,
Vaessen Christophe,
Seisen Thomas,
de La Taille Alexandre,
Roupret Morgan
Publication year - 2021
Publication title -
the international journal of medical robotics and computer assisted surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.556
H-Index - 53
eISSN - 1478-596X
pISSN - 1478-5951
DOI - 10.1002/rcs.2201
Subject(s) - medicine , pyeloplasty , interquartile range , surgery , ureteropelvic junction , perioperative , radiological weapon , hydronephrosis , retrospective cohort study , urinary system
Abstract Background Robot‐assisted pyeloplasty (RALP) for patients with clinically symptomatic ureteropelvic junction obstruction (UPJO) is increasing and needs assessment. Methods Patients who underwent RALP for UPJO in two academic centres were included. Demographic and perioperative data were collected retrospectively. UPJO was evaluated by imaging pre‐ and post‐surgery. Patients had follow‐up consultations 3,6 and 12 months post‐surgery. Global success was defined as a clinical response plus radiographic evidence of no further obstruction 3‐months post‐surgery. Results Overall 214 patients (median age: 40 years [interquartile range:30.3–54.0]) were included. Fourteen patients (6.5%) had undergone previous surgery for UPJO. Thirty patients (14%) suffered complication: urinoma ( n = 13; 6.1%), pyelonephritis ( n = 15; 7%) and retroperitoneal haematomas ( n = 2; 0.9%). Repeated early surgery was necessary in eight patients (3.6%). Seven patients had a recurrence of UPJO and six (2.9%) underwent repeated surgery. Radiological success rate was 96.7% whereas global success rate was 91%. Conclusions RALP was a reliable, effective and safe treatment for UPJO with a high global and radiologic success rate.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here